厄贝沙坦治疗高血压伴慢性心力衰竭患者的疗效及其对血清hs-CRP和BNP水平的影响

摘要

Objective To study the curative effect of irbesartan in the hypertension complicated with chronic heart failure and its influence in the level of hs-CRP and BNP.Methods 72 hypertension patients complicated with chronic heart failure were selected. The patients were randomly divided into test group and control group, 36 cases each group. The test group adopted the conventional therapy combined with irbesartan; the control group just adopted the conventional therapy. After treatment, the improvement of cardiac function as well as the level of hs-CRP and BNP for two groups was analyzed.Results Experimental group total effectiveness 97.22% compared with the control group total effectiveness 83.33% has obvious advantages, cardiac function and the experimental group after treatment serum hs - CRP (4.83±1.29)mg/L, the BNP (103.75±25.80)mg/L, compared with control group (5.78 ± 1.72)mg/L, (177.49±25.17)mg/L significantly decreased(P<0.05).Conclusion Irbesartan can efficiently improve the patient’s cardiac function and reduce the level of hs-CRP and BNP. It is worthy of clinical promotion and application.%目的：探讨厄贝沙坦治疗高血压伴慢性心力衰竭患者的疗效及其对血清hs-CRP和BNP水平的影响。方法选取高血压合并慢性心力衰竭的患者72例，随机分为实验组和对照组，各36例，实验组采取常规治疗并加用厄贝沙坦，对照组采取常规治疗。对治疗后2组心功能的改善以及hs-CRP和BNP水平进行分析。结果实验组总有效率97.22%相比于对照组总有效率83.33%有明显的优势，并且治疗后实验组血清hs-CRP （4.83±1.29）mg/L、BNP（103.75±25.80）mg/L相比于对照组（5.78±1.72）mg/L、（177.49±25.17）mg/L明显降低，差异有统计学意义（P<0.05）。结论厄贝沙坦可有效改善患者心脏功能，并降低患者hs-CRP、BNP水平，值得临床推广应用。